RTOG 0522: huge Investment in patients and resources and no benefit with addition of cetuximab to radiotherapy--why did this occur?
- PMID: 25713440
- DOI: 10.1200/JCO.2014.59.6908
RTOG 0522: huge Investment in patients and resources and no benefit with addition of cetuximab to radiotherapy--why did this occur?
Comment in
-
Reply to D. Adkins et al.J Clin Oncol. 2015 Apr 1;33(10):1225-6. doi: 10.1200/JCO.2014.59.9449. Epub 2015 Feb 23. J Clin Oncol. 2015. PMID: 25713435 No abstract available.
-
Reply to D. Adkins et al.J Clin Oncol. 2015 Apr 1;33(10):1224-5. doi: 10.1200/JCO.2014.59.9431. Epub 2015 Feb 23. J Clin Oncol. 2015. PMID: 25713438 No abstract available.
Comment on
-
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.J Clin Oncol. 2014 Sep 20;32(27):2940-50. doi: 10.1200/JCO.2013.53.5633. J Clin Oncol. 2014. PMID: 25154822 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
